NCT05656027

Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 469 (actual)
• Sponsor: LENZ Therapeutics, Inc · Academic / Other
• Sex: All
• Age: 45 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.

Detailed description

Phase 3 study to evaluate the safety and effectiveness of LNZ101 compared with LNZ100 and Brimonidine for the treatment of Presbyopia.

Conditions

• Presbyopia
• Refractive Error
• Eye Diseases
• Near Vision

Interventions

Type	Name	Description
DRUG	Aceclidine+Brimonidine combination ophthalmic solution	LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
DRUG	Aceclidine ophthalmic solution	LNZ100 Aceclidine ophthalmic solution
DRUG	Brimonidine	Brimonidine ophthalmic solution

Timeline

• Start date: 2022-12-19
• Primary completion: 2023-12-15
• Completion: 2024-01-25
• First posted: 2022-12-19
• Last updated: 2026-02-25
• Results posted: 2026-02-25

Locations

25 sites across 1 country: United States

Regulatory

• FDA-regulated drug study